As early as 2008, Maheswaran S, et al. noticed that 4 of 27 patients with NSCLC after 3 months of EGFR TKI therapy had significantly lower numbers of CTCs captured by a microfluidic device than that in the samples before therapy [39]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.